Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330

2.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
4.

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.

Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.

5.

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.

Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.

Leukemia. 2005 Oct;19(10):1774-82.

PMID:
16136169
6.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

7.

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.

Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.

Oncogene. 2010 Feb 4;29(5):739-51. doi: 10.1038/onc.2009.374. Epub 2009 Nov 2.

PMID:
19881535
8.

Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.

Gu JJ, Santiago L, Mitchell BS.

Blood. 2005 Apr 15;105(8):3270-7. Epub 2004 Dec 16.

9.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11. Epub 2004 Dec 30.

10.

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.

Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11.

11.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

12.

Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.

Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.

Mutat Res. 2006 Jan 31;603(1):74-82. Epub 2006 Jan 4.

PMID:
16388976
13.

Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells.

Bandyopadhyay G, Biswas T, Roy KC, Mandal S, Mandal C, Pal BC, Bhattacharya S, Rakshit S, Bhattacharya DK, Chaudhuri U, Konar A, Bandyopadhyay S.

Blood. 2004 Oct 15;104(8):2514-22. Epub 2004 Jun 29.

14.

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.

Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A.

Cancer Res. 2006 Feb 15;66(4):2305-13.

15.

Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons.

Lekmine F, Uddin S, Sassano A, Parmar S, Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN, Platanias LC.

J Biol Chem. 2003 Jul 25;278(30):27772-80. Epub 2003 May 20.

16.

Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.

Parmar S, Smith J, Sassano A, Uddin S, Katsoulidis E, Majchrzak B, Kambhampati S, Eklund EA, Tallman MS, Fish EN, Platanias LC.

Blood. 2005 Oct 1;106(7):2436-43. Epub 2005 Mar 24.

17.

Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.

Li J, Xue L, Hao H, Han Y, Yang J, Luo J.

Oncol Rep. 2012 Feb;27(2):461-6. doi: 10.3892/or.2011.1502. Epub 2011 Oct 12.

PMID:
21993902
18.

BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.

Andreu EJ, Lledó E, Poch E, Ivorra C, Albero MP, Martínez-Climent JA, Montiel-Duarte C, Rifón J, Pérez-Calvo J, Arbona C, Prósper F, Pérez-Roger I.

Cancer Res. 2005 Apr 15;65(8):3264-72.

19.

Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.

Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.

Oncogene. 2007 Apr 12;26(17):2445-58. Epub 2006 Oct 9.

PMID:
17043649
20.

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.

Cancer Biol Ther. 2014 Feb;15(2):207-15. doi: 10.4161/cbt.26725. Epub 2013 Nov 8.

Supplemental Content

Support Center